140 related articles for article (PubMed ID: 3764334)
1. Dose response studies using desferrioxamine and orally active chelators in a mouse model.
Kontoghiorghes GJ
Scand J Haematol; 1986 Jul; 37(1):63-70. PubMed ID: 3764334
[TBL] [Abstract][Full Text] [Related]
2. Orally active alpha-ketohydroxypyridine iron chelators: studies in mice.
Kontoghiorghes GJ
Mol Pharmacol; 1986 Dec; 30(6):670-3. PubMed ID: 3785144
[TBL] [Abstract][Full Text] [Related]
3. In vivo evaluation of hydroxypyridone iron chelators in a mouse model.
Gyparaki M; Porter JB; Hirani S; Streater M; Hider RC; Huehns ER
Acta Haematol; 1987; 78(2-3):217-21. PubMed ID: 3120475
[TBL] [Abstract][Full Text] [Related]
4. Selection of a new generation of orally active alpha-ketohydroxypyridine iron chelators intended for use in the treatment of iron overload.
Kontoghiorghes GJ; Barr J; Nortey P; Sheppard L
Am J Hematol; 1993 Apr; 42(4):340-9. PubMed ID: 8493983
[TBL] [Abstract][Full Text] [Related]
5. Effective chelation of iron in beta thalassaemia with the oral chelator 1,2-dimethyl-3-hydroxypyrid-4-one.
Kontoghiorghes GJ; Aldouri MA; Hoffbrand AV; Barr J; Wonke B; Kourouclaris T; Sheppard L
Br Med J (Clin Res Ed); 1987 Dec; 295(6612):1509-12. PubMed ID: 3122880
[TBL] [Abstract][Full Text] [Related]
6. Iron chelation studies using desferrioxamine and the potential oral chelator, 1,2-dimethyl-3-hydroxypyrid-4-one, in normal and iron loaded rats.
Kontoghiorghes GJ; Sheppard L; Hoffbrand AV; Charalambous J; Tikerpae J; Pippard MJ
J Clin Pathol; 1987 Apr; 40(4):404-8. PubMed ID: 3584483
[TBL] [Abstract][Full Text] [Related]
7. Orally active alpha-ketohydroxypyridine iron chelators: effects on iron and other metal mobilisations.
Kontoghiorghes GJ
Acta Haematol; 1987; 78(2-3):212-6. PubMed ID: 3120474
[TBL] [Abstract][Full Text] [Related]
8. 1,2-Dimethyl-3-hydroxypyrid-4-one, an orally active chelator for treatment of iron overload.
Kontoghiorghes GJ; Aldouri MA; Sheppard L; Hoffbrand AV
Lancet; 1987 Jun; 1(8545):1294-5. PubMed ID: 2884415
[TBL] [Abstract][Full Text] [Related]
9. Orally active alpha-ketohydroxy pyridine iron chelators intended for clinical use: in vivo studies in rabbits.
Kontoghiorghes GJ; Hoffbrand AV
Br J Haematol; 1986 Apr; 62(4):607-13. PubMed ID: 3964556
[TBL] [Abstract][Full Text] [Related]
10. Effect of novel 1-alkyl-3-hydroxy-2-methylpyrid-4-one chelators on uptake and release of iron from macrophages.
Brock JH; Licéaga J; Arthur HM; Kontoghiorghes GJ
Am J Hematol; 1990 May; 34(1):21-5. PubMed ID: 2327400
[TBL] [Abstract][Full Text] [Related]
11. Comparative efficacy and toxicity of desferrioxamine, deferiprone and other iron and aluminium chelating drugs.
Kontoghiorghes GJ
Toxicol Lett; 1995 Oct; 80(1-3):1-18. PubMed ID: 7482575
[TBL] [Abstract][Full Text] [Related]
12. Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular function in beta-thalassaemia.
Anderson LJ; Wonke B; Prescott E; Holden S; Walker JM; Pennell DJ
Lancet; 2002 Aug; 360(9332):516-20. PubMed ID: 12241655
[TBL] [Abstract][Full Text] [Related]
13. The effect of 2,4-dihydroxypyridine-N-oxide, a new orally active iron chelator, on iron excretion in mice.
Kontoghiorghes GJ
Clin Chim Acta; 1987 Mar; 163(2):137-41. PubMed ID: 3568416
[TBL] [Abstract][Full Text] [Related]
14. Relative oral efficacy and acute toxicity of hydroxypyridin-4-one iron chelators in mice.
Porter JB; Morgan J; Hoyes KP; Burke LC; Huehns ER; Hider RC
Blood; 1990 Dec; 76(11):2389-96. PubMed ID: 2257308
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of combined desferrioxamine and deferiprone versus single desferrioxamine therapy in patients with major thalassemia.
Zareifar S; Jabbari A; Cohan N; Haghpanah S
Arch Iran Med; 2009 Sep; 12(5):488-91. PubMed ID: 19722772
[TBL] [Abstract][Full Text] [Related]
16. A comparison of the iron-clearing properties of 1,2-dimethyl-3-hydroxypyrid-4-one, 1,2-diethyl-3-hydroxypyrid-4-one, and deferoxamine.
Bergeron RJ; Streiff RR; Wiegand J; Luchetta G; Creary EA; Peter HH
Blood; 1992 Apr; 79(7):1882-90. PubMed ID: 1558978
[TBL] [Abstract][Full Text] [Related]
17. [Treatment of iron overload states with oral administration of the chelator agent, L1 (Deferiprone)].
Cermák J; Brabec V
Vnitr Lek; 1994 Sep; 40(9):586-90. PubMed ID: 7975362
[TBL] [Abstract][Full Text] [Related]
18. Deferiprone versus desferrioxamine in thalassaemia, and T2* validation and utility.
St Pierre TG
Lancet; 2003 Jan; 361(9352):182; author reply 183-4. PubMed ID: 12531617
[No Abstract] [Full Text] [Related]
19. Liposome entrapped desferrioxamine and iron transporting ionophores: a new approach to iron chelation therapy.
Young SP; Baker E; Huehns ER
Br J Haematol; 1979 Mar; 41(3):357-63. PubMed ID: 427040
[TBL] [Abstract][Full Text] [Related]
20. Antioxidant and free radical scavenging activities of the iron chelators pyoverdin and hydroxypyrid-4-ones in iron-loaded hepatocyte cultures: comparison of their mechanism of protection with that of desferrioxamine.
Morel I; Cillard J; Lescoat G; Sergent O; Pasdeloup N; Ocaktan AZ; Abdallah MA; Brissot P; Cillard P
Free Radic Biol Med; 1992 Nov; 13(5):499-508. PubMed ID: 1334028
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
